Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Inmune Bio ( (INMB) ).
On February 19, 2026, INmune Bio announced plans to host a webinar on February 26, 2026, to present new clinical data on its CORDStrom cell therapy candidate for recessive dystrophic epidermolysis bullosa. The MissionEB Phase III trial data to be discussed underscore CORDStrom’s positioning as a systemic, disease-modifying alternative to topical standards of care in this rare, severe skin disorder.
The event will feature clinical investigators from the U.K.-based MissionEB study, including lead pediatric RDEB specialist Dr. Anna Martinez and INmune Bio co-founder and chief scientific officer Prof. Mark Lowdell. They are expected to detail outcomes such as improvements in EBDASI skin scores, pediatric weight gain, reductions in pain and itch, and enhanced quality-of-life measures, highlighting potential implications for treatment paradigms and patient management if the therapy ultimately proves successful.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Score is held back primarily by weak financial performance (large losses and sustained cash burn). The latest earnings call provides a meaningful offset via improved quarterly loss profile, stated cash runway into late 2026, and defined regulatory milestones, while technicals are mixed and valuation is constrained by negative earnings and no dividend.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. is a NASDAQ-listed, clinical-stage biotechnology company focused on developing therapies that target the innate immune system to treat inflammatory, autoimmune and cancer indications. Its product platforms include CORDStrom, a pooled allogeneic umbilical cord-derived mesenchymal stromal cell therapy, XPro for selectively neutralizing soluble TNF, and INKmune, a cell-based medicine aimed at enhancing natural killer cell activity in oncology.
The company leverages proprietary screening, pooling and expansion technologies to manufacture off-the-shelf, cGMP-produced cellular medicines designed for consistency, scalability and cost efficiency. Its CORDStrom platform, initially developed as a disease-agnostic cell therapy, can be tuned for indication-specific effector functions such as anti-inflammatory, immunomodulatory and wound-healing properties, with recent randomized trial work completed in recessive dystrophic epidermolysis bullosa (RDEB).
Average Trading Volume: 393,239
Technical Sentiment Signal: Sell
Current Market Cap: $37.22M
Find detailed analytics on INMB stock on TipRanks’ Stock Analysis page.